Physician profile
Shakera Headley
NPI 1831805001
$1,818.17
in general payments reported to CMS, 2019-2025
21 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $113 · 2024: $781 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.95 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $554.82 | 2024-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $157.29 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $127.56 | 2023-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $127.46 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.99 | 2024-2025 | |
| Beta Bionics, INC. | $101.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $93.65 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.57 | 2024-2025 | Jardiance |
| Sequel Med Tech, LLC | $76.94 | 2025 | Twiist |
| Antares Pharma, INC. | $54.04 | 2024-2025 | Xyosted |
| Cequr Corporation | $52.21 | 2024-2025 | Cequr Simplicity |
| Soleno Therapeutics, INC. | $48.54 | 2025 | Vykat Xr |
| Dexcom, INC. | $43.53 | 2024-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $42.94 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $32.68 | 2025 | Tymlos |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.98 | 2024 | |
| Medtronic, INC. | $24.75 | 2023 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $19.29 | 2025 | Unithroid |
| Tolmar, INC. | $18.02 | 2024 | |
| Rgh Enterprises LLC | $16.14 | 2025 | |
| Acella Pharmaceuticals, LLC | $14.25 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shakera Headley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.